ORLANDO, Fla., Nov 4 (Reuters) - A key study finding that Eli Lilly and Co's (LLY.N: Quote, Profile, Research) experimental anti-clotting drug boosts the risk of serious bleeding compared to the standard therapy prompted Wall Street analysts to question the outlook for the product on Sunday.
